Introduction: Reducing low-density lipoprotein cholesterol (LDL-C) with lipid-lowering
therapies has been associated with a decrease in the frequency of cardiovascular events …

Introduction: Statins are powerful lipid-lowering agents which reduce cardiovascular (CV)–
related morbidity and mortality. However, a large proportion of patients cannot attain the …

Purpose The aim of this study was to evaluate the safety and efficacy of combination
treatment of rosuvastatin with ezetimibe in patients with primary hypercholesterolemia …

Purpose The aim of this study was to evaluate the efficacy and tolerability of
rosuvastatin/ezetimibe combination therapy in Korean patients with high cardiovascular risk …

Cardiovascular disease is one of the leading causes of death around the world with various
efforts being made to reduce risk in patients through preventive measures. One major …

Rosuvastatin/ezetimibe combines two lipid-lowering agents: rosuvastatin, an HMG-CoA
reductase inhibitor (ie statin) with particularly strong inhibitory effects on hepatic cholesterol …

Aim We aimed to compare the effects of fixed‐dose combinations of ezetimibe plus
rosuvastatin to rosuvastatin alone in patients with primary hypercholesterolemia, including a …

Purpose The goal of this study was to compare the lipid-lowering efficacy of the combination
of ezetimibe and low-or intermediate-intensity statin therapy versus that of high-intensity …

Purpose Combination therapy with ezetimibe and statins is recommended in cases of statin
intolerance or insufficiency. The objective of this study was to compare the efficacy and …

Purpose We investigated whether the combination therapy of low-intensity rosuvastatin and
ezetimibe is an useful alternative to moderate-intensity rosuvastatin monotherapy in patients …